about
The effects of the coverage gap on drug spending: a closer look at Medicare Part DComparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data.Pharmaceutical Use and Spending Trend in Medicare Beneficiaries With Dementia, From 2006 to 2012.The effect of Medicare Part D on drug and medical spending.How the Medicare Part D drug benefit changed the distribution of out-of-pocket pharmacy spending among older beneficiaries.A simple change to the Medicare Part D low-income subsidy program could save $5 billion.The Medicare drug benefit (Part D) and treatment of heart failure in older adults.Employee choice of a high-deductible health plan across multiple employersThe impact of Medicare Part D on medication treatment of hypertension.Potential savings from greater use of $4 generic drugs.Use of intelligent assignment to Medicare Part D plans for people with schizophrenia could produce substantial savings.Impact of Medicare Part D on antidepressant treatment, medication choice, and adherence among older adults with depression.Use of prescription drug samples and patient assistance programs, and the role of doctor-patient communication.Explaining Improved Use of High-Risk Medications in Medicare Between 2007 and 2011.Evaluating the Initiation of Novel Oral Anticoagulants in Medicare Beneficiaries.Trends in Use of Medications for Smoking Cessation in Medicare, 2007-2012Trends in Off-Label Use of Second-Generation Antipsychotics in the Medicare Population From 2006 to 2012.Geographic variation in Medicare drug spendingThe financial burden from prescription drugs has declined recently for the nonelderly, although it is still high for many.Part D Plan Switching Among Medicare Beneficiaries With Schizophrenia.The vast majority of Medicare Part D beneficiaries still don't choose the cheapest plans that meet their medication needs.Comparing local and regional variation in health care spendingHypertension Prevalence, Awareness, Treatment, and Control Following China's Healthcare Reform.Are Drugs Substitutes or Complements for Intensive (and Expensive) Medical TreatmentAmbulatory antibiotic use and prescription drug coverage in older adults.Race/Ethnicity, disability, and medication adherence among medicare beneficiaries with heart failure.The impact of Medicare Part D on medication adherence among older adults enrolled in Medicare-Advantage products.Geographic variation in the quality of prescribing.Geographic Variation in the Use of Oral Anticoagulation Therapy in Stroke Prevention in Atrial Fibrillation.Anticipatory Behavior in Response to Medicare Part D's Coverage Gap.Comparing the Approval and Coverage Decisions of New Oncology Drugs in the United States and Other Selected Countries.Evaluating the Effects of Pioneer Accountable Care Organizations on Medicare Part D Drug Spending and Utilization.Trends in the Inclusion of Mental Health Providers in Medicare Shared Savings Program ACOs.Anticoagulation Use and Clinical Outcomes After Major Bleeding on Dabigatran or Warfarin in Atrial Fibrillation.Effects of Public Hospital Reform on Inpatient Expenditures in Rural China.Comparing Advanced Practice Providers and Physicians as Providers of e-Visits.Comparing clinical and economic outcomes of biologic and conventional medications in postmenopausal women with osteoporosis.Risk of Bleeding With Dabigatran in 2010-2011 Medicare Data.Determinants of willingness to pay for self-paid vaccines in China.Using predictive analytics and big data to optimize pharmaceutical outcomes.
P50
Q24632713-EE962C51-7A96-4A17-8B91-2627DAF86879Q31131255-B39BA20F-E052-4442-ADC0-22C17C611620Q33610481-5DAB10AC-BBA2-47F3-AE68-40C1E72A192AQ33810332-CDE0054C-0217-44DC-A956-06336214A6B3Q33906706-8F775C60-4874-4AF7-8CB4-1E61141A9014Q33924929-3A094C16-1E72-4A50-8FAC-6598CC2EB641Q33967679-7EAFFA7A-6DD8-4A77-A10F-E61408F722EFQ34554686-E1BF136C-F7DB-4CD1-8342-E92D63EA059DQ34554697-027CE81B-2B39-496B-A8F4-0FF10C8F88C2Q34780469-BE87A6F5-6498-4287-8D8D-8657922E8341Q35146113-3FA11D9B-4184-4476-A014-0386A4773895Q35602002-A9E926E3-4D95-446E-B624-018195CAB79CQ35606857-D0B6770F-AB29-4588-8E84-8AE357C0431BQ35965226-5790EBCE-9C8D-444E-9360-C416EEE1BEC1Q35966238-3C66F133-8956-4930-9310-C2CEF6391E97Q35977030-6C12A790-F61C-4F71-AB9E-BF5698D943F0Q35990340-59301E4B-DDB0-4C4E-BFE5-C417422A3F86Q35999455-2DC2248A-5B01-4A0B-97D2-886B41F57459Q36070889-40434EE3-9358-4A2D-9E33-D9544F7FDA24Q36113078-5FC5EE6F-8CE0-447F-9A31-3ADFDD82766FQ36314839-F28BA069-A87C-4C39-B82E-1DAEE4AC9773Q36374918-0E102890-BA89-405D-9834-D97108FFBAF4Q36950135-72BF4045-9F8D-462B-B905-5926604F655AQ37186245-EE7A3E0D-504A-463E-9662-4D713B66051EQ37199714-C6D19353-6BE4-4FD3-A7EF-13CB5D725594Q37663100-314D2BED-262C-44B9-9378-F7982A4F3F4BQ37731247-354A8E19-BF18-4D82-A34F-BC586B0A14F5Q37806771-1F35BB0D-C3CE-4111-A3C5-A58BB43503FAQ38665890-B9576753-8CEE-4C6D-B183-132B8E1FB94CQ38922568-C8C141B8-5050-45DD-B1C1-F7C658A3056AQ38997569-A8A9B404-5E9A-4834-A522-B7D14F135028Q39036167-7BFF0F80-B7D9-4AB1-8353-1DB2369B0EB1Q39043268-5856E56B-4E66-4F66-A09E-5009ACD13B80Q39137944-07D3BA3E-E33B-4722-8971-58CF951A7EBDQ40026683-99DFFDDA-9C32-43D6-974F-86229CA491EDQ40751473-180A0DA1-303B-4634-ABEC-C1A6D74566F5Q40852576-EFC7D236-16B7-49AA-8D3A-24D1C082C5CDQ42345865-898D049F-1D8F-4C36-AE33-B19AF39FF9F6Q43170025-C76BBF44-9B09-486A-8B59-EBD4CFD43C06Q45939234-0CA49153-64CA-4D0F-9E19-EC0F4CF14EFB
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Yuting Zhang
@ast
Yuting Zhang
@en
Yuting Zhang
@es
Yuting Zhang
@nl
Yuting Zhang
@sl
type
label
Yuting Zhang
@ast
Yuting Zhang
@en
Yuting Zhang
@es
Yuting Zhang
@nl
Yuting Zhang
@sl
prefLabel
Yuting Zhang
@ast
Yuting Zhang
@en
Yuting Zhang
@es
Yuting Zhang
@nl
Yuting Zhang
@sl
P214
P106
P1153
35975503900
P214
P31
P496
0000-0002-6460-6779
P7859
viaf-186552812